Verastem Oncology Q2 2026 Results: AVMAPKI FAKZYNJA Sales Growth Extends Cash Runway

Key Points

• Verastem Oncology reported $25.1 million in Q2 2026 net product revenue from AVMAPKI FAKZYNJA CO-PACK, up 34% sequentially from $18.7 million in Q1.
• Total revenue reached $40.1 million, including a $15 million milestone payment tied to global COPIKTRA sales.
• The company reported $201.4 million in pro forma liquidity and expects this funding, anticipated product revenue, and access to additional financing to support operations into the second half of 2027.

Verastem Oncology (Nasdaq: VSTM) reported meaningful commercial progress in the second quarter of 2026, led by continued sales growth for AVMAPKI FAKZYNJA CO-PACK. The oncology company also advanced its clinical pipeline and strengthened its financial position, giving it additional runway to support product commercialization and development programs.

 AVMAPKI FAKZYNJA CO-PACK revenue rises 34% from Q1

AVMAPKI FAKZYNJA CO-PACK generated $25.1 million in net product revenue during the second quarter, compared with $18.7 million in the first quarter of 2026. The 34% quarter-over-quarter increase was driven by new patient starts and a growing number of refills, signaling broader adoption following the product’s U.S. launch.

The therapy is approved for adults with KRAS-mutated recurrent low-grade serous ovarian cancer. Since its launch, AVMAPKI FAKZYNJA CO-PACK has generated approximately $74.5 million in cumulative net product revenue, making commercial execution the company’s most important near-term driver.

 Total revenue benefits from a $15 million COPIKTRA milestone

Verastem reported total revenue of $40.1 million for the quarter, compared with $2.1 million in the prior-year period. Alongside AVMAPKI FAKZYNJA CO-PACK sales, Q2 revenue included a $15 million payment from Secura Bio after COPIKTRA reached $200 million in cumulative worldwide net sales.

The milestone payment provides a meaningful boost to reported quarterly revenue, but it is not recurring. For investors evaluating the company’s underlying commercial trajectory, AVMAPKI FAKZYNJA CO-PACK product revenue remains the more important figure to watch.

 Cash position supports commercialization and clinical development through 2027

Verastem ended the quarter with $136.4 million in cash, cash equivalents, and investments. Including the $15 million milestone payment and a planned $50 million initial royalty-financing tranche, subject to closing conditions, the company’s pro forma liquidity totaled $201.4 million as of June 30, 2026.

Management expects this capital, projected product revenue, and potential access to an additional financing tranche to fund operations into the second half of 2027. The extended cash runway is designed to give Verastem time to grow its commercial business and advance key clinical programs without an immediate need to raise equity capital.

 TARGET-D 202 trial expands Verastem’s pipeline in solid tumors

Beyond its commercial launch, Verastem is advancing avutometinib-based treatment combinations for patients with RAS/MAPK pathway-driven cancers. The company recently dosed the first patient in the TARGET-D 202 Phase 2 study, which is evaluating these combinations in advanced solid tumors.

Pipeline progress could create longer-term value, although clinical development remains inherently uncertain. In the nearer term, investors will likely focus on the pace of AVMAPKI FAKZYNJA CO-PACK sales growth, refill trends, gross-to-net dynamics, and Verastem’s ability to execute on upcoming clinical milestones within its projected funding runway.